Small molecule modulators that restore CFTR function not only improve the clinical status of CF patients with responsive mutations but also influence fatty acid imbalance and levels of various complex lipids in humans with CF [4,21] and in cultured CF cells [14,22]. This evidence concerns the gene CFTR and cystic fibrosis.